Introduction
Despite a century's worth of global economic and social development, the enduring problems of malnutrition, lack of sanitation, and poor education have provided fertile ground for the myriad parasitic diseases that afflict the world's most vulnerable populations. Hookworms, blood-feeding intestinal nematodes, currently infect over 700 million persons in developing countries [1 . . ,2]. Substantial reduction of hookworm disease will likely require the joining of conventional control methods with novel drugs and/or vaccines. Toward that goal, the past year has seen notable advances in our understanding of hookworms that are likely to prove useful in future eradication efforts. This review will focus on recent developments in the following areas: (1) epidemiology of hookworm infection; (2) identification of virulence factors involved in hookworm pathogenesis; (3) treatment and prevention; and (4) research aimed at developing vaccines against hookworm.
The majority of human hookworm infections are caused by Ancylostoma duodenale or Necator americanus [3] . Upon contact with the skin, infectious third-stage larvae (L3) penetrate the epidermis and invade the circulation. The worms are carried to the heart, then the lungs, where they enter the alveolar spaces. The parasites migrate to the trachea and are swallowed, undergoing two molts to the adult blood-feeding stage upon reaching the small intestine. There they mate and females begin to produce eggs, which are excreted in the feces. The egg hatches in the soil, releasing a larva that undergoes two molts to become L3. The adult hookworm attaches to the intestinal mucosa where it chews and digests the plug of tissue within its buccal capsule, lacerating capillaries in the process (Fig. 1 ). Blood is sucked into and around the mouth opening as the worm feeds, leading to loss of red blood cells and serum proteins. The major clinical features of chronic hookworm infection are anemia and malnutrition, which are associated with varying degrees of cognitive and growth delay in children [4, 5 . ].
Epidemiology of hookworm infection
A recent analysis of existing data by de Silva et al. [1 . . ] estimates the global hookworm prevalence at approximately 740 million people throughout the tropics and subtropics. Over the past decade, hookworm prevalence has declined in most regions; however, given the population increases during the same interval, it seems that the total number of infections worldwide has actually increased. Furthermore, even in countries with relatively low overall prevalence there may be regions with much higher infection levels, necessitating targeted control efforts. Such regional variability is typified by a recent study of schoolchildren in rural and semi-urban areas of central Cambodia which demonstrated hookworm prevalences ranging from 5 to 65% [6 . ]. Likewise, a much larger-scale survey of 29 Vietnamese provinces demonstrated an even greater prevalence range of 0-85% [7 . ]. In addition to the well-documented risk factors of poverty and poor sanitary infrastructure and/or practices, factors influencing regional hookworm prevalence may also include local climate and soil composition, with higher prevalence observed in areas possessing sandy (as opposed to high-clay) soils, warmer temperatures, and greater rainfall [8] .
In addition to regional variability, a recent study by Utzinger et al. [9] has demonstrated that hookworm prevalence and intensity may vary considerably within a single village. The factors influencing such local variability were not evaluated, although lower awareness of proper sanitary practices has been shown in other studies to correlate with elevated infection rates [10] . The value of education was also underscored by a comprehensive study of risk factors for soil-transmitted helminth infection in Indian tea-growers, where higher levels of education predicted lower hookworm prevalence and infection intensity [11] .
Although immunoepidemiological studies have previously demonstrated that hookworm-infected humans produce parasite-specific humoral and cellular immune responses [12] , only recently has the cytokine profile of such persons been systematically evaluated. Geiger et al.
[13
. . ] have demonstrated that peripheral blood mononuclear cells from N. americanus-infected subjects show reduced proliferation (compared to uninfected controls) when exposed to a mitogen or hookworm antigen preparation. In addition, peripheral blood mononuclear cells from infected individuals produced more proinflammatory tumor necrosis factor-a, as well as greater amounts of the regulatory cytokine interleukin-10 than those from controls. Examination of other cytokines demonstrated impaired production of the type 1 cytokines interleukin-12 and interferon-g, as well as the type 2 cytokines interleukin-5 and interleukin-13 in infected individuals compared to controls. The authors hypothesized that the enhanced interleukin-10 secretion in the patients may play a role in the observed suppression of the type 1 and 2 cytokines, possibly as a mechanism to dampen potentially pathological inflammatory responses. In support of this, parasite-induced interleukin-10 has been shown to protect mice from allergic responses [14] , and may provide some explanation for lower levels of allergic responses observed in children infected with geohelminths [15 .
, 16] . Increased levels of tumor necrosis factor-a observed in hookworminfected individuals most likely reflect an ongoing intestinal inflammatory process, which is consistent with preliminary data we have recently obtained in an animal model of ancylostomiasis. Taken together, these data suggest that hookworm infection elicits a mixed systemic cytokine profile that results in both protective and potentially deleterious inflammatory immune responses.
Molecular pathogenesis of hookworm disease
Upon attachment to the host intestine, adult hookworms secrete numerous proteins that are thought to facilitate parasite feeding and survival, thus contributing to the pathogenesis of anemia and malnutrition. The past year has seen a rapid advance in our understanding of the molecules secreted by adult hookworms at the site of intestinal attachment. Much of this work has focused on the mechanisms by which hookworms inhibit thrombosis -a phenomenon first recognized nearly 100 years ago [17] . To date, multiple anticoagulants that target coagulation factor Xa and/or the coagulation factor VIIa-tissue factor complex have been isolated from the dog hookworm Ancylostoma caninum and the human parasite Ancylostoma ceylanicum. In the past year, two additional coagulation factor VIIa-tissue factor complex inhibitors have been cloned from A. caninum [18 . ], along with a novel hookworm platelet inhibitor (HPI) [19] . Interestingly, immunolocalization studies have revealed that the factor Xa and factor VIIa-tissue factor inhibitors localize to different structures in A. caninum (the secretory cephalic glands and the esophagus, respectively), suggesting complementary, rather than redundant, roles for these molecules in vivo [18 . ]. Recent comparative studies confirm that the major anticoagulant secreted by A. ceylanicum, which exhibits activity against both factor Xa and factor VIIa-tissue factor, acts by a mechanism that is distinct from the dog hookworm inhibitors [20] . The fact that hookworms have evolved multiple mechanisms to interfere with host hemostasis suggests a critical role for blood-feeding in these parasites and these antithrombotics may provide unique targets for novel drugs and/or vaccines. Furthermore, these molecules have recently shown promise as therapeutic agents for a broad array of human diseases associated with activation of thrombosis, including cardiovascular disease, sepsis, and even Ebola virus infection [21 . ,22] .
Although the nutritional requirements of hookworms have not been clearly defined, it is logical to presume that red blood cells and serum proteins comprise a substantial component of the hookworm diet (Fig. 1) . This is supported by findings that hookworms produce numerous proteases with demonstrated ability to degrade hemoglobin in vitro, and that many of these proteases are associated with the parasite's intestinal tract [23 . . ] . Experiments by Williamson et al. have provided compelling evidence that hemoglobin is degraded by a multi-enzyme cascade that is similar to that employed by the malarial parasite Plasmodium falciparum [24] . The relative efficiency of certain hookworm digestive proteases has also been proposed to influence host specificity [23 . . ]. This concept is illustrated by studies demonstrating that aspartic proteases from the anthrophilic N. americanus digested human hemoglobin more efficiently than hemoglobin from nonpermissive dogs [25, 26] . In light of their potential role in parasite digestion, hemoglobin-degrading proteases are attractive vaccine candidates (see below).
Adult hookworms also produce molecules that appear to target a variety of innate host defenses found in the mammalian intestine. The A. ceylanicum Kunitz-type inhibitor (AceKI), is a potent, broad-spectrum inhibitor of the pancreatic digestive enzymes trypsin, chymotrypsin, and elastase [27] . AceKI localizes to the subcuticle of the adult hookworm, suggesting that it may neutralize intestinal proteases at the external surface of the parasite, presumably protecting it from proteolysis [28 . . ]. In light of its activity in vitro and source of production, we hypothesized that AceKI might also impair host absorption of nutrients, perhaps contributing to hookworm-associated malnutrition. This hypothesis was confirmed by studies demonstrating that immunization with recombinant AceKI confers protection against hookworm-associated growth delay, but not anemia, thus defining its likely role in disease pathogenesis.
In addition to the proteins of known activity discussed above, hookworms produce various secretory molecules whose biological functions have yet to be elucidated. The Ancylostoma-secreted proteins (ASPs) ASP-1 and ASP-2 are members of a family of related cysteine-rich proteins secreted by both L3 and adult hookworms [29 . . ,30 . ]. The ASPs are the predominant proteins secreted by activated L3, and localize to a variety of structures within the adult worm, including secretory glands, cuticles, and intestinal brush border. As no defined function or host target has been elucidated for the ASP proteins, it remains unclear what role these major secretory proteins play in hookworm biology or disease pathogenesis. However, the fact that these compounds show amino acid sequence homology to previously identified hookworm inhibitors of mammalian integrins a IIb /b III (hookworm platelet inhibitor [19] ) and CD11b/CD18 (neutrophil inhibitory factor [31] ) suggest a potential role in blocking cellular interactions mediated by these multifunctional mammalian signaling receptors.
A number of novel low-molecular-weight excretory/ secretory molecules have been purified from A. ceylanicum excretory/secretory products using reversed-phase high-performance liquid chromatography (HPLC). A. ceylanicum excretory-secretory protein 1 (AceES-1) is the predominant protein secreted by the adult hookworm [32] , while a second molecule, named AceES-2 [33 . . ], is the immunodominant component of A. ceylanicum excretory/secretory products. As neither molecule has any significant amino acid homology to previously identified proteins, it remains to be determined what their respective roles in hookworm pathogenesis may be. However, our demonstration that oral immunization with recombinant AceES-2 confers partial protection against hookworm anemia suggests a possible role in bloodfeeding. What this chromatographic approach to antigen identification has demonstrated is that hookworm excretory/secretory products contain a vast array of novel compounds, and further elucidation of their specific roles in vivo will undoubtedly provide new insight into the host-parasite interaction and pathogenesis of hookworm disease.
Treatment and prevention
Community-based chemotherapy using the benzimidazole anthelminthics (albendazole or mebendazole) remains the only currently available approach for controlling hookworm infection in developing countries [34, 35] . These drugs are generally safe and effective at reducing both the prevalence and intensity of infections, and in the short term can lead to improvements in blood hemoglobin levels and growth [36, 37] . A recent study by Stoltzfus et al. [38 . . ] found that quarterly treatment of Zanzibari preschool children with mebendazole improved growth, appetite, and anemia over a 1-year study period. Most interestingly, the authors observed an unexpectedly significant decrease in malnutrition and anemia following mebendazole treatment among children younger than 30 months of age, who paradoxically were among the most lightly infected. The authors hypothesized that one potential explanation for the unexpected benefit of anthelminthic treatment in this group could be that even light infections in young children may be associated with significant systemic inflammation, thus leading to growth delay and anemia independent of blood loss per se. This work would seem to corroborate the findings of Geiger et al. [13 . . ], as well as our observations of inflammatory cytokine gene expression in the hamster model of A. ceylanicum.
Unfortunately, the long-term benefits of anthelminthic treatment programs have been somewhat more difficult to quantify. Although the studies discussed above support the value of anthelminthic treatment in hookworm-endemic areas, recent work by Albonico et al. [39 . . ] has suggested that repeated use of such drugs may lead to lower efficacy. The study, conducted in a Zanzibari population that had been exposed to a program of mebendazole treatment every 4-6 months for the previous 5 years, found that the cure rate (7.6%) and eggreduction rate (52.1%) for hookworm infection had been significantly reduced from preprogram levels (22.4 and 82.4%, respectively). These findings raise the troubling possibility that emerging drug resistance may hamper future chemotherapy-based control efforts, and recent work has been carried out aimed at identifying the genetic basis of benzimidazole resistance in human hookworm isolates [40] . The prospect of drug resistance underscores the need to develop additional strategies for the control of hookworm, as well as other soiltransmitted nematode infections.
Vaccine development
Given the obvious and pressing need for novel hookworm-control methods, considerable interest has been focused on the evaluation of molecules that may be exploited as vaccine antigens [5 . ,29
. .
]. Over the past year results for several candidate antigens have been published (Table 1) . Ac-MTP-1, a metalloprotease secreted by activated A. caninum L3, was evaluated in the dog model of A. caninum [41] . Dogs injected with recombinant Ac-MTP-1 developed high-titer IgG2 antibody responses that were inversely correlated with intestinal worm burdens and fecal egg counts upon challenge infection. The dog model has also been employed to evaluate the potential of Ac-CP-2, a gutassociated cysteine protease from A. caninum [42 . ]. Immunization of dogs with recombinant Ac-CP-2 yielded IgG antibodies that neutralized the enzyme's N. americanus AceES-2 ASP-1-6 Ay-ASP-1 and -2 Na-ASP L3, third-stage larvae; HPI, hookworm platelet inhibitor; AceES, Ancylostoma ceylanicum excretory-secretory protein; Ac-MTP-1, a metalloprotease secreted by activated Ancylostoma caninum L3; Ac-CP-2, a gut-associated cysteine protease from A. caninum; ASP, Ancylostoma-secreted protein; AceKI, A. ceylanicum Kunitz-type inhibitor; AceAP, A. ceylanicum anticoagulant peptide; AcAP, A. caninum anticoagulant peptide; Ac-MEP-1, A. caninum metalloendopeptidase-1; Na-APR-2, N. americanus aspartic protease-2; Ac-APR, A. caninum aspartic protease; Ac-TMP, A. caninum tissue inhibitor of matrix metalloproteases; Ay-ASP, A. ceylanicum ASP; Na-ASP, N. americanus ASP. activity in vitro and bound to the gut of hookworms that subsequently fed on the vaccinated animals. Although no reductions in total intestinal hookworm burden were observed following challenge of the vaccinated dogs, the worms were generally smaller, the male/female ratio was increased, and fewer eggs were produced than in control dogs.
Recent studies have also evaluated candidate vaccine antigens in the hamster model of A. ceylanicum infection [43] . This model has distinct advantages in that it is less expensive than the dog model, and employs a hookworm species for which humans are fully permissive hosts. Vaccination of hamsters with the recombinant ASP-2 from A. ceylanicum led to a 32% reduction in adult-worm burden following challenge infection. Although this reduction in worm burden was not associated with statistically significant improvements in anemia or growth delay, immunized animals exhibited reduced spleen sizes, perhaps indicative of a reduced level of systemic inflammation. Interestingly, the beneficial effect of immunization was only seen in animals that received the adjuvant Quil-A, as the group immunized with recombinant ASP-2 in alum were not protected.
Two adult-stage antigens from A. ceylanicum have recently shown promise as candidate vaccines. We have demonstrated that subcutaneous immunization with the inhibitor of pancreatic enzymes AceKI (in alum) reduces hookworm-associated growth delay following challenge infection [28 . . ]. Interestingly, this effect occurred independent of anemia, suggesting that the pathogenesis of the two major clinical sequelae of hookworm infection, i.e. anemia and growth delay, are attributable to distinct mechanisms. We have also demonstrated that a single oral immunization using the secreted protein recombinant AceES-2, delivered without adjuvant, is associated with improved hemoglobin status upon challenge [33 . . ]. The most promising aspect of the recombinant AceES-2 vaccine study is its suggestion that mucosal immunization, which has not previously been reported for a recombinant hookworm antigen, may provide an effective 'needle-free' vaccine strategy. Taken together, these data confirm the utility of the hamster vaccine model for both defining the role of pathogenesis of specific hookworm proteins, as well as evaluating potential vaccine candidates.
Conclusion
Although hookworm remains among the most prevalent infections of humans, the concerted efforts of a small number of dedicated research groups have nonetheless advanced our understanding of the epidemiology and pathogenesis of disease. Thus, considerable progress towards reducing the global health impact is being made both in the field and in the laboratory. Further epidemiological study should help ensure that scarce treatment resources are directed to populations with the greatest potential to benefit. Moreover, it is imperative that basic research aimed at elucidating pathogenesis and exploiting the molecular vulnerabilities of the parasite be encouraged in order to identify novel approaches to control, and ultimately eradicate, this great scourge of humanity.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as: 
